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Abstract 30 
Removal and storage of ovarian cortical tissue is currently offered to young female cancer 31 
patients undergoing potentially sterilizing chemotherapy and/or radiotherapy. For patients at 32 
high risk of re-introduction of malignancy through auto-transplantation, the ultimate aim is to 33 
achieve complete oocyte development from this tissue in vitro. The ability to develop human 34 
oocytes from the earliest follicular stages through to maturation and fertilisation in vitro 35 
would revolutionise fertility preservation practice. This has been achieved in mouse where in 36 
vitro grown (IVG) oocytes from primordial follicles have resulted in the production of live 37 
offspring.  Systems that support growth and development of oocytes from human ovarian 38 
cortex are being developed by several groups. This review focuses on the steps required to 39 
recapitulate in vitro the process of human oocyte development from the primordial stage and 40 
the systems currently available to support this. 41 
42 
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Introduction 43 
 The ability to develop human immature oocytes in vitro would have many 44 
potential applications but would be of particular relevance to Fertility Preservation. Ovarian 45 
tissue cryopreservation is now an option for women with cancer prior to undergoing 46 
gonadotoxic treatments (1). Re-implantation of cryo-preserved tissue is currently the only 47 
option to use stored tissue but in many cases, particularly for women with Leukemia, 48 
malignant cells are present in the ovary therefore, re-implantation is not an option, however, 49 
the oocytes within this tissue could potentially be grown in vitro (1). Culture systems with the 50 
aim of achieving in vitro growth (IVG) of immature oocytes to maturity and subsequent 51 
fertilization in vitro (IVF) have been the subject of research for almost 40 years. Several 52 
systems that support the growth of later stages of follicle development from rodents have 53 
been developed (2-8) with some reporting the production of live young (3, 4, 6-8). Complete 54 
development from the most immature oocytes (primordial stages) in vitro with subsequent 55 
IVF of oocytes followed by embryo transfer and production of offspring has been achieved in 56 
the mouse using a two step culture system (9, 10). The initial studies resulted in the birth of 57 
one mouse which developed abnormalities as an adult (9). Following alterations to the culture 58 
medium several mouse embryos and offspring have been obtained using IVG oocytes then 59 
combined with in vitro maturation (IVM) and IVF (10). More recently, in vitro systems that 60 
support complete development of murine oocytes starting from induced pluripotent stem cells 61 
(11) and from primordial germ cells (12) have been reported and these systems have resulted 62 
in competent oocytes that produce embryos and live young. 63 
  The work on rodents has provided proof of principle and has encouraged the challenge of 64 
adapting these systems to support human oocyte development in vitro. IVG of primordial 65 
follicles would be of particular benefit to pre-pubertal girls undergoing fertility preservation 66 
before being exposed to damaging chemotherapy (13). Currently the only fertility 67 
preservation option for pre-pubertal girls is storage of ovarian cortical tissue with the 68 
potential for re-implantation at a later time (13). In cases where re-implantation is not 69 
possible, IVG could provide another option to restore fertility. For IVG to be clinically 70 
viable, the process would need to start with primordial follicles as cortical strips that are 71 
stored contain predominantly this stage. Whilst there still remains much detailed research to 72 
be carried out before IVG of primordial follicles could ever be clinically applied, a great deal 73 
of progress has been made in developing culture techniques to support human oocyte 74 
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development in vitro. In this review the current status of human IVG from primordial 75 
follicles will be considered. 76 
 77 
Stages of Follicle Development 78 
The majority of follicles within the ovary in all young mammalian females will be at the 79 
primordial stage of development and these follicles are continually utilised throughout 80 
reproductive life (14). It is not known whether the pool of primordial follicles represents a 81 
homogeneous population but at this stage follicles have not yet been exposed to selection 82 
processes that lead to follicle degeneration (15, 16). Primordial follicles represent a “resting” 83 
population of germ cells (oocyte arrested at dictyate stage of Prophase 1 of meiosis 84 
surrounded by a few flattened granulosa cells), that are formed pre-natally. Recruitment into 85 
growth takes place throughout the woman’s reproductive life and a sequence of precisely 86 
regulated processes is required for complete oocyte/follicle development to occur. The 87 
sequence starts with (a) initiation of primordial follicle growth and development to the 88 
preantral follicle stage; (b) growth of the preantral stage with formation of a fluid filled cavity 89 
(antrum) and expansion to the pre ovulatory or Graafian follicle stage (c) rupture of the 90 
Graafian follicle releasing a cumulus-oocyte complex at ovulation in response to the mid-91 
cycle LH surge (17, 18).  92 
The oocyte is held in meiotic arrest as it grows within the follicle and it must acquire the 93 
ability to resume meiosis (meiotic competence) as well as the ability to support fertilisation 94 
and embryonic development (developmental competence). Oocyte development is dependent 95 
upon the environment of the individual follicle for its function as a gamete and this is 96 
regulated by inhibitory and stimulatory endocrine, paracrine and autocrine signalling by the 97 
somatic cells of the follicle (granulosa and surrounding theca cells) enhanced by several 98 
oocyte specific factors mediated through bi-directional communication (19, 20). The 99 
physiological requirements of the oocyte, granulosa and theca cells are extremely complex 100 
and dynamic therefore recapitulating the process of follicle activation and growth in vitro is 101 
one of the greatest technical challenges in reproductive technology (18). 102 
  103 
Growing Human follicles in vitro 104 
Several approaches have been taken to support early human follicle development in vitro 105 
starting with primordial follicle activation (21-31). Whilst there are several culture systems 106 
that support a specific stage of human oocyte development in vitro, there is so far only one 107 
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report that supports human primordial follicles to the stage of meiotic maturation (30). To 108 
achieve complete development of human oocytes in vitro a multi-step culture system is 109 
required (26, 30, 32). The first step in this process is to facilitate the initiation of primordial 110 
follicle development and support early growth; the second step is to optimise the growth of 111 
follicles from preantral to antral stages; step 3 supports the completion of oocyte growth 112 
ready for in vitro maturation in step 4 (Figure 1). In optimising a culture system to obtain 113 
developmentally competent oocytes the focus should be on oocyte development and this may 114 
preclude the need to develop large follicular structures in vitro. The multi-step approach 115 
needs to support the changing requirements of the developing oocyte and its surrounding 116 
somatic (granulosa) cells whilst maintaining good oocyte-somatic cell interactions. 117 
Therefore, providing conditions that support the maintenance of appropriately differentiated 118 
somatic cells in contact with the developing oocyte similar to the oocyte granulosa cell 119 
complexes in the rodent system is essential (4, 10). 120 
  121 
IVA: In vitro Activation of human primordial follicles 122 
The majority of follicles within ovarian cortical tissue will be at the quiescent primordial 123 
stage. Activation of primordial follicles in vitro (IVA) and early follicle development are key 124 
features of any IVG system. Human primordial follicles can be activated and grow well 125 
within mechanically loosened cortical pieces, developing to multilaminar preantral 126 
(secondary) stages within 6 days (26, 30).  Central to this process is preparation of the 127 
ovarian tissue. This involves removal of most of the underlying stromal tissue and any 128 
growing follicles so that the cultured tissue consists of ovarian cortex containing primordial 129 
and primary follicles. When these small fragments of human ovarian cortex are cultured there 130 
is a significant shift of follicles from the quiescent to the growing pool over short periods of 6 131 
– 10 days (26, 29-31).  132 
It remains unclear how follicle activation is controlled but it is known to involve a 133 
combination of inhibitory, stimulatory and maintenance factors (33). The importance of the 134 
phosphatidylinositol-3’-kinase (PI3K-AKT) signalling pathway within the oocyte has been 135 
implicated in  regulating  activation of primordial follicles using mouse knockout models (34) 136 
and in human using culture of ovarian cortex (29, 35, 36). The phosphatase and tensin 137 
homolog deleted on chromosome ten (PTEN) acts as a negative regulator of this pathway and 138 
suppresses initiation of follicle development (34). The transcription factor Forkhead Protein 139 
O3 (FOXO3) is a downstream effector of this pathway and acts to inhibit follicle recruitment 140 
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(37). Other components of this pathway are dependent on the mammalian target of rapamycin 141 
complex 1 (mTORC1), a serine/threonine kinase that regulates cell growth and proliferation 142 
in response to growth factors and nutrients and also regulates primordial follicle activation 143 
(38). From knockout mouse data it appears that whilst PTEN within the oocyte suppresses 144 
activation of primordial follicles mTORC promotes it. How these pathways regulate human 145 
follicle development is unclear but culture models facilitate the study of these processes (29, 146 
36, 39).  147 
Significant primordial follicle activation occurs in step one of the multi-step culture system 148 
(26, 30). This activation appears to be as a result of disrupting the Hippo signalling pathway 149 
during the preparation of the tissue (36, 40, 41). Hippo disruption increases expression of 150 
downstream growth factors but manipulation of the PI3K pathway results in further activation 151 
(29, 35, 36, 40, 41). Inhibition of PTEN in cultured human ovarian cortex results in increased 152 
activation of primordial follicles and more secondary follicles but subsequent growth and 153 
survival of isolated secondary follicles is compromised (29, 36). The detrimental effect on 154 
secondary follicles may be as a result of alterations in DNA damage and repair responses as 155 
demonstrated recently in a bovine culture model (42).  156 
 157 
Cortical strip culture removes follicles from the in vivo endocrine and paracrine processes 158 
regulating growth rate; however, follicles will still be subject to the effect of follicle 159 
interactions and the influence of stromal cell factors. It is clear that tissue shape and stromal 160 
density are important factors that contribute to the regulation of follicle growth initiation in-161 
vitro, as solid cubes of cortical tissue show lesser growth initiation (21) than cortex cultured 162 
as flattened “sheets,” where much of the underlying stroma is removed (26, 30). The physical 163 
environment of the follicles within the cortical tissue affects their response to stimulatory and 164 
inhibitory factors and therefore influences their ability to grow (43).  Once follicle growth has 165 
been initiated within cortical tissue they can develop to multi-laminar stages but do not 166 
survive well within the cortical environment as growth is inhibited resulting in loss of follicle 167 
integrity and oocyte survival (22, 26). Growing follicles need to be released from the cortical 168 
stromal environment and cultured individually to limit the effect of follicle interactions (26, 169 
30, 31, 44). 170 
 171 
IVG: In vitro Growth of human preantral follicles 172 
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Preantral follicles can be isolated from cortical tissue post culture by mechanical dissection, 173 
enzymatic isolation or a combination of both. Collagenase and DNase can be used to remove 174 
preantral follicles from stromal tissue, however collagenase can cause damage which leads to 175 
poor survival of follicles (45). The presence of theca layers is required for growing follicles 176 
to retain their structure and survive the second stage of IVG and these may be compromised 177 
by collagenase (45). More purified enzyme preparations such as Liberase may avoid the 178 
damage that occurs with Collagenase (46, 47). Mechanical isolation of follicles has the 179 
advantage of preserving follicular integrity by maintaining the basal lamina and thecal layers, 180 
however the procedure is laborious and results in a low yield (26, 30).  181 
 182 
Supporting the growth of human preantral follicles in vitro has led to the development of 183 
matrices to maintain follicle structure. Alginate hydrogels has been used to encapsulate 184 
human preantral follicles and support their growth in vitro (48).  Alginate encapsulation is 185 
thought to mimic the extra cellular matrix in vivo in terms of its ability to facilitate molecular 186 
exchange between the follicle and the culture medium whilst its flexibility can accommodate 187 
cell proliferation but its rigidity prevents dissociation of the follicular unit. The rigidity of the 188 
alginate capsule affects follicle development as inhibition of growth and reduced 189 
steroidogenesis have been reported in murine follicles embedded in 1% alginate gels (49) 190 
whereas fully grown human oocytes have been produced using 0.5% gels (48).  191 
The application of tissue engineering to support the growth of isolated follicles has been 192 
making progress; decellularized ovarian tissue and 3D micro-porous scaffolds are being 193 
explored as matrices to support preantral follicle growth (50, 51). Recent work has explored 194 
the production of electrospun patterned porous scaffolds which may be more accessible and 195 
reproducible than decellularised tissue (52).  Engineered scaffolds clearly have great potential 196 
and should be developed further to support human follicle growth in vitro.  197 
 The multi-step culture system that has been developed for human follicles (30) does not use 198 
matrices or scaffolds to support the growth of isolated preantral follicles. Isolated growing 199 
follicles are cultured in v-shaped micro-well plates and this has supported follicular 200 
architecture in vitro whilst promoting growth, differentiation and antral formation (26, 30).  201 
 202 
Once follicles are isolated from the ovarian cortex their progression in vitro is remarkable. 203 
Secondary human follicles isolated enzymatically from fresh ovarian tissue and cultured in 204 
the presence of Follicle Stimulating Hormone (FSH), become steroidogenically active and 205 
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complete oocyte growth within 30 days (48) and these oocytes have been shown to be 206 
capable of meiotic maturation (53). Primordial follicles grown within fragments of ovarian 207 
cortex to multi-laminar stages which are then isolated without the use of enzymes and 208 
cultured in the presence of Activin and FSH become steroidogenic within 10 days of in vitro 209 
growth (26, 30).  210 
During step 2 of the multi-step system, isolated follicles cultured individually form antral 211 
cavities within 6-8 days. At this stage oocyte-granulosa cell complexes can be retrieved by 212 
applying gentle pressure to the follicle. Complexes with complete cumulus and adherent 213 
mural granulosa cells are selected for step 3 of the multi-step system (Figure 1) (30). Step 3 214 
involves culturing the complexes on membranes in the presence of Activin-A and rhFSH for 215 
up to 4 days until oocytes reach a diameter of 100 microns (30).  216 
 217 
 That in vitro grown follicles can produce fully grown oocytes after a relatively short culture 218 
period confirms that local ovarian factors inhibit follicle development in vivo. Oocyte size is 219 
an indicator of its ability to resume meiosis therefore sustaining oocyte growth is the major 220 
objective of any complete in vitro development system (17). There are clearly differences in 221 
growth rate depending on whether the whole follicle is cultured (48, 53) or whether, 222 
complexes are removed for further growth after an antral cavity has formed (26, 30).  223 
Whether the growth rate observed in vitro should be characterised as accelerated is not clear. 224 
The rate observed represents uninhibited growth without brakes that are required in vivo to 225 
regulate follicle development within the context of the reproductive cycle. Comparisons of 226 
culture systems is needed to determine optimal conditions but at this time there is only one 227 
complete system that supports growth from human primordial to maturation (30).  The next 228 
step is to determine whether the growth pattern in vitro can support the development of 229 
healthy oocytes or whether it is deleterious to oocyte function, epigenetic changes and health.  230 
 231 
Meiotic Maturation of Oocytes from IVG human follicles  232 
The final stage in the IVG process before IVF can take place is IVM to support resumption of 233 
meiosis to the point of Metaphase II (Figure 1). IVM has been a successful strategy for 234 
embryo production in domestic species and has been applied to human oocytes with varying 235 
degrees of success (54, 55).  The first live birth after IVM of immature oocytes was reported 236 
in 1991 (56), although IVM was being utilised during the early development of IVF  (57). 237 
IVM is performed in a limited number of centres and success rates vary with the main factor 238 
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being oocyte source and stage (55). The rate of maturation of immature oocytes remains 239 
below that of oocytes harvested from stimulated ovaries, indicating that the protocols are sub-240 
optimal or many of the harvested oocytes are intrinsically unable to undergo maturation (54, 241 
55).  242 
 243 
IVG oocytes derived from the multistep culture system undergo meiotic maturation following 244 
an IVM protocol (30). These oocytes form Metaphase II spindles but emit abnormally large 245 
polar bodies (30). Polar body size is influenced by the proximity of the spindle to the oocyte 246 
cortex and the inter-chromosomal spacing within Metaphase II spindles (58). If there is a loss 247 
of spindle contact with the oocyte cortex this can lead to extrusion of large polar bodies (59). 248 
The cause of the large polar bodies in the IVG derived oocytes is not known but it indicates 249 
that culture conditions need to be further optimised. The consequences of such abnormalities 250 
on chromosome balance in mature oocytes needs to be investigated. 251 
Whilst acknowledging that there are no fully optimised culture systems for human oocytes 252 
there is now proof of concept that complete in vitro growth of human oocytes is possible 253 
(30). The end point of any IVG system is to produce developmentally competent and 254 
epigenetically normal oocytes therefore future research needs to focus on optimising each of 255 
the stages and to gain further understanding of the epigenetic status of IVG oocytes and of 256 
any embryos formed (60).  257 
   258 
Summary 259 
The most significant clinical application of in vitro growth (IVG) of human oocytes is in 260 
Fertility Preservation given the widespread adoption of ovarian tissue cryopreservation for 261 
cancer patients (1). It is clear that making a good egg is not an easy or straightforward 262 
process (18).  If reliable methodology could produce in vitro generated mature human 263 
oocytes capable of fertilisation this would be a viable alternative to autologous 264 
transplantation.  Apart from the clinical implications and potential of the various in vitro 265 
growth systems; each of them provide access to the process of human oogenesis in an 266 
experimentally tractable paradigm. Through these systems we will gain greater understanding 267 
of human oocyte development which will ultimately lead to improvements in Fertility 268 
Preservation. 269 
 270 
 271 
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FSH                   Follicle Stimulating Hormone 426 
FOXO3              Forkhead box protein O3 427 
IVA                    In Vitro Activation 428 
IVG                    In Vitro Growth 429 
IVF                     In Vitro Fertilisation 430 
IVM                    In Vitro Maturation 431 
PI3K-AKT         Phosphatidylinositol-3’-kinase and Protein Kinase B 432 
PTEN                 The phosphatase and tensin homolog deleted on chromosome ten  433 
mTORC1            Mammalian target of rapamycin complex 1  434 
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 440 
Figure 1:  Diagrammatic representation of a multi-step culture system to support in vitro 441 
growth (IVG) of oocytes from human primordial follicles through to maturation as described 442 
by McLaughlin et al., 2018. Step 1, in vitro activation within micro-cortex for 7 days (a)  then 443 
micro-dissection of multi-laminar growing follicles to be placed in step 2 (b) and cultured 444 
individually until antral formation occurs (c) Step 3, Isolation of the oocyte granulosa 445 
complex (d) from the intact follicle for further growth on membranes for up to 4 days (e). 446 
Step 4, Oocyte-Cumulus complexes placed within medium for in vitro maturation (IVM). 447 
Oocytes are then analysed for the presence of a Metaphase II spindle and a polar body. 448 
Fertilisation of IVG human oocytes has not yet been tested. 449 
 450 
